Research
Awakening the T lymphocyte response
T-ONE Therapeutics’ goal is to develop more effective therapies to fight cancer and autoimmune diseases.
The breakthrough novelty resides in the identification of LINE1 transcripts as the first of a new class of immune response inhibitors that regulate T cell exhaustion by controlling their gene expression profiles. These results could revolutionise current immunotherapies with novel RNA-based therapies aimed at awakening the T lymphocyte effector response at the transcriptional level.
With our experimental approach we aim to produce new drugs for immunotherapy through the exploitation of antisense oligonucleotides (ASOs), in order to achieve a higher patient response rate and to reduce the side effects reported so far, thus improving patients’ quality of life.
The discovery was published in Nature Genetics
Marasca F, Sinha S, Vadalà R, Polimeni B, Ranzani V, Paraboschi E, Burattin FV, Ghilotti M, Crosti MC, Negri ML, Campagnoli S, Notarbartolo S, Bianchi AS, Siena S, Prati D, Montini G, Viale G, Torre O, Harari S, Grifantini R, Soldà G, Biffo S, Abrignani S, Bodega B.
Nature Genetics, 17 January 2022 · doi: 10.1038/s41588-021-00989-7